299 related articles for article (PubMed ID: 31023560)
1. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer.
Groot VP; Blair AB; Gemenetzis G; Ding D; Burkhart RA; Yu J; Borel Rinkes IHM; Molenaar IQ; Cameron JL; Weiss MJ; Wolfgang CL; He J
Eur J Surg Oncol; 2019 Sep; 45(9):1674-1683. PubMed ID: 31023560
[TBL] [Abstract][Full Text] [Related]
2. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
Wijetunga AR; Chua TC; Nahm CB; Pavlakis N; Clarke S; Chan DL; Diakos C; Maloney S; Ashrafi-Zadeh A; Kneebone A; Hruby G; Jamieson NB; Gill A; Mittal A; Samra JS
Eur J Surg Oncol; 2021 Oct; 47(10):2543-2550. PubMed ID: 33952409
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
[TBL] [Abstract][Full Text] [Related]
4. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
[TBL] [Abstract][Full Text] [Related]
5. Continued adjuvant FOLFIRINOX for BRPC or LAPC after neoadjuvant FOLFIRINOX.
Park J; Kim HY; Na HY; Lee JS; Lee JC; Kim JW; Yoon YS; Hwang JH; Han HS; Kim J
J Cancer Res Clin Oncol; 2023 May; 149(5):1765-1775. PubMed ID: 35723728
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
7. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.
Takahashi S; Kinoshita T; Konishi M; Gotohda N; Kato Y; Kinoshita T; Kobayashi T; Mitsunaga S; Nakachi K; Ikeda M
J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):567-74. PubMed ID: 21331805
[TBL] [Abstract][Full Text] [Related]
8. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
[TBL] [Abstract][Full Text] [Related]
9. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
Barnes CA; Aldakkak M; Christians KK; Clarke CN; Dua K; George B; Ritch PS; Kamgar M; Hall WA; Kulkarni N; Erickson BA; Evans DB; Tsai S
Surgery; 2020 Sep; 168(3):440-447. PubMed ID: 32641278
[TBL] [Abstract][Full Text] [Related]
10. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
Kwon D; McFarland K; Velanovich V; Martin RC
Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
[TBL] [Abstract][Full Text] [Related]
11. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
12. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.
Greer SE; Pipas JM; Sutton JE; Zaki BI; Tsapakos M; Colacchio TA; Gibson JJ; Wiener DC; Ripple GH; Barth RJ
J Am Coll Surg; 2008 Mar; 206(3):451-7. PubMed ID: 18308215
[TBL] [Abstract][Full Text] [Related]
13. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective.
Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA
Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192
[TBL] [Abstract][Full Text] [Related]
14. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer.
Wo JY; Niemierko A; Ryan DP; Blaszkowsky LS; Clark JW; Kwak EL; Lillemoe KD; Drapek LN; Zhu AX; Allen JN; Faris JE; Murphy JE; Nipp R; Fernandez-Del Castillo C; Ferrone CR; Hong TS
Am J Clin Oncol; 2018 Jul; 41(7):656-661. PubMed ID: 28134673
[TBL] [Abstract][Full Text] [Related]
15. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.
Javed AA; Wright MJ; Siddique A; Blair AB; Ding D; Burkhart RA; Makary M; Cameron JL; Narang A; Herman J; Zheng L; Laheru D; Weiss MJ; Wolfgang C; He J
J Gastrointest Surg; 2019 Jan; 23(1):112-121. PubMed ID: 30242644
[TBL] [Abstract][Full Text] [Related]
16. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity.
Hill CS; Rosati LM; Hu C; Fu W; Sehgal S; Hacker-Prietz A; Wolfgang CL; Weiss MJ; Burkhart RA; Hruban RH; De Jesus-Acosta A; Le DT; Zheng L; Laheru DA; He J; Narang AK; Herman JM
Ann Surg Oncol; 2022 Apr; 29(4):2456-2468. PubMed ID: 35129721
[TBL] [Abstract][Full Text] [Related]
18. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer.
Mellon EA; Strom TJ; Hoffe SE; Frakes JM; Springett GM; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
J Gastrointest Oncol; 2016 Aug; 7(4):547-55. PubMed ID: 27563444
[TBL] [Abstract][Full Text] [Related]
19. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer.
Blair AB; Yin LD; Pu N; Yu J; Groot VP; Rozich NS; Javed AA; Zheng L; Cameron JL; Burkhart RA; Weiss MJ; Wolfgang CL; He J
Ann Surg; 2021 Jul; 274(1):162-169. PubMed ID: 32304375
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
